Drug Discovery and Development

Is the hype surrounding biosimilars real or simply a hopeful view on an exceedingly expensive drug market? Read this article to find out more about biosimilars and understand the challenges facing the biosimilars industry.

In this podcast, learn more about biomarkers and their importance in clinical trials and how data-rich tools are being used to collect and curate the vast amounts of publicly available information about biomarkers.

Our resident gene editing expert, Dr. Yann Jouvenot, provides an overview of CRISPR gene editing and how it is affecting how research and development are being performed in the Biotech and Pharma industries.

The typical success rate of a clinical trial is less than ten percent. Pharmaceutical companies are using a variety of methods to save time and reduce costs to get drugs to market faster. Biomarker screening is proving to be an effective way to improve the drug discovery and development process. See one of the ways Pharma companies can identify the most relevant biomarkers.

Our resident gene editing expert, Dr. Yann Jounenvat, provides an overview of the four main gene editing techniques that are being used in life science research today. Learn about the pros and cons of each of method and where they are best applied.

Gene augmentation and antisense therapies treat disease by providing a functional copy of faulty gene or repressing its expression. Find out how gene editing tools, like CRISPR, promise a more permanent cure.

Ligand binding assays are utilized throughout the large-molecule drug development process. However, their robustness, accuracy, and reproducibility depend on the quality of critical reagents. See how you can ensure their consistent characterization, particularly during early drug development stages.

Better model systems and faster, more comprehensive screens are only two of the many ways in which CRISPR is changing the pace of discovery. See how CRISPR is transforming research and development by providing us with tools that were once unimaginable.

CRISPR has revolutionized gene editing but is not the only way to edit a gene. We compare the pros and cons of four main gene editing techniques – meganucleases, zinc finger nucleases, TALENs, and CRISPR-Cas9 – discuss the advance of these methods to the clinic for therapeutic applications, and introduce newer technologies that eliminate some of the pitfalls of current techniques.

Striving for efficiency in workflow is not a new concept. Automation and use of smart technologies in industries such as automotive and shipping, and services like USPS and UPS, have drastically changed the way they function today not just with innovation but with personalization. Pharma is beginning to understand the need for adopting personalized workflow as well. Now, what can Pharma learn from these industries and how can it apply it to the industry?